drugset / Trial / NCT04184115
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
Timeline
- Start
- 2019-06-09
- Primary completion
- 2019-06-11
- Completion
- 2019-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Scopolamine | Unknown | 0.2 mg | Intranasal |
| Subject | Scopolamine | Unknown | 1.5 mg | Intranasal |